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Background: Morquio A syndrome (or mucopolysaccharidosis IVa) is an ultra-rare multi-organ disease, resulting in
significantly impaired functional capacity, mobility and quality of life (QoL).
Methods: This patient-reported outcomes survey evaluated the global burden of Morquio A among adults
(≥18 years, N = 27) and children (7-17 years, N = 36), including the impact on mobility, QoL, pain and fatigue.
QoL was assessed using the general Health-Related Quality of Life (HRQoL) questionnaire (the EuroQol [EQ]-5D-5L).
Pain and pain interference with daily activities were assessed using the Brief Pain Inventory Short Form (BPI-SF) in
adults and the Adolescent Pediatric Pain Tool (APPT) in children. Fatigue was assessed by questioning the patients
on the number of evenings in a week they felt extremely tired.
Results: The clinical data showed a wide heterogeneity in clinical manifestations between patients, with the
majority of patients showing differing levels of endurance, short stature, bone and joint abnormalities, abnormal
gait and eye problems. Mobility was considerably impaired: 44.4% of children and 85.2% of adult patients were
using a wheelchair. High wheelchair reliance significantly reduced QoL. This was mainly driven by reduced scores in
the Mobility, Self-care, and Usual Activity domains. The HRQoL utility values were 0.846, 0.582 and 0.057 respectively
in adults not using a wheelchair, using a wheelchair only when needed and always using a wheelchair; values were
0.534, 0.664 and –0.180 respectively in children. Employed adult patients had a better HRQoL than unemployed
patients (HRQoL utility value 0.640 vs. 0.275, respectively).
64% of children and 74% of adult patients had joint pain; fatigue was reported by 69% of children and 63% of
adults. Overall, increased mobility was associated with more severe and widespread pain and more fatigue.
Conclusions: The HRQoL of Morquio A patients is mainly driven by the ability to remain independently mobile
without becoming wheelchair dependent. Their QoL reduces dramatically if they always have to use their
wheelchair. Even a slightly better mobility (wheelchair use only when needed) greatly improves QoL. Maintenance
of functional capacity and mobility paired with better pain management are likely to improve QoL.
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Morquio A syndrome, or mucopolysaccharidosis (MPS)
IVa, is an ultra-rare, inherited lysosomal storage dis-
order caused by a deficiency in the enzyme N-acetylga-
lactosamine-6-sulfatase (GALNS). This leads to impaired
degradation of the glycosaminoglycans (GAGs) chondroitin-
6-sulfate (CS) and keratan sulfate (KS) [1,2] and disruption
of the extracellular matrix function. Patients with Morquio
A typically show widespread skeletal and joint abnor-
malities, including dwarfism with short trunk and neck,
genu valgum, hip dysplasia, joint hypermobility, spinal
abnormalities and pectus carinatum [3,4]. These skeletal
abnormalities generally result in impaired endurance,
walking ability and gait. Cardiopulmonary disease (inclu-
ding tracheal stenosis/malacia and dyspnoea) and spinal
cord compression may further reduce endurance and/or
mobility [5]. Many patients with Morquio A will sooner or
later need walking aids or a wheelchair to assist with mo-
bility [3,4]. The clinical manifestations of the disease and
resulting impaired mobility can reduce the patient’s ability
to perform activities of daily living (ADL) [4], such as at-
tendance at school or work and social activities, and may
have a considerable impact on the quality of life (QoL) of
the patient, close relatives and caregivers. The patient’s
QoL can be further compromised by frequent infections,
impaired vision or hearing, frequent surgeries and (joint)
pain and/or fatigue [3,4,6]. As Morquio A patients retain
normal intelligence [6], adult patients are often employed
and functioning in society, as long as physically capable.
Therefore, reduced physical functioning/mobility may not
only impact on the patient’s QoL but may also require a
significant amount of care and increase the burden on so-
ciety as a whole.
There is a tremendous variation between Morquio A
patients, in terms of spectrum of clinical manifestations/
organ systems involved, severity of manifestations and
progression rate [6]. The life expectancy of patients with
Morquio A also varies considerably, with some patients
surviving until the second or third decade of life and
others with near-normal life expectancy [4].
This patient-reported outcomes (PRO) survey was set-
up to assess the global burden of disease among patients
with Morquio A, including the impact on mobility/
wheelchair use, HRQoL, pain and fatigue and the inter-
action between these factors.
Methods
Study design and patient selection
The study was an international, voluntary, single-
assessment, cross-sectional paper-based survey admin-
istered in person or by mail via local staff members of
MPS patient advocacy/support groups and/or physi-
cians and clinics. The study took place from June 2012
to April 2013.The study population consisted of Morquio A patients
and their caregivers identified by patient advocacy/support
groups and/or physicians/clinics from Brazil, Colombia,
Germany, Spain, Turkey and the UK. These countries
have strong patient advocacy/support groups and a fair
number of patients. Eligible patients had to be ≥ 7 years of
age (some exceptions were made due to the limited num-
ber of patients) and treatment-naïve, i.e. not on enzyme
replacement therapy. Caregivers (≥18 years old) who
served as the primary caregiver of at least one patient with
Morquio A were recruited after enrolment of a family
member with Morquio A in the survey. Eligible patients
and caregivers had to be able to speak, write and under-
stand both the verbal and written language of their coun-
try. All were informed on all pertinent aspects of the
study and were willing to participate and complete the
surveys. All patients and caregivers who met the study
entry criteria and completed the survey were included in
the analysis. The low number of UK patients in this cohort
can be explained by the fact that many of the patients
were part of the different enzyme replacement therapy
clinical trials and the fact that the phase 1/2 enzyme re-
placement therapy study was performed in the UK only.
Assessments
Two survey versions for patients, one for adult patients
(≥ 18 years) and one for “children” (≤ 17 years old), and
one caregiver survey were used. If a patient was unable
to physically complete the surveys, the survey adminis-
trators recorded verbatim responses from the patient.
Child surveys were completed by the patient with assist-
ance from a parent or carer, if necessary. Ethics approval
was obtained in Germany and all patients (or their care-
givers) signed an informed consent/ascent form. No eth-
ics approval was required in the other countries, due to
the survey nature of the study.
The patient surveys were developed through review of
the existing literature to understand the clinical and hu-
manistic impacts of Morquio A and to identify the most
relevant generic, disease-specific and symptom-specific
PROs. They consisted of stand-alone and validated HRQoL
questionnaires. Stand-alone questions were developed
jointly by BioMarin Europe Ltd, the UK MPS Society
and some clinical experts treating Morquio A patients.
Pilot questionnaires were assessed among adult patients
in the UK through two focus groups who judged their
clarity, relevance and value. Additionally, the groups
identified important questions that were not included in
the questionnaire and questions that could be deleted to
reduce respondent burden. The questionnaires were re-
vised and finalised based on the feedback obtained. The
questionnaires were developed in English and translated
and culturally adapted to each targeted country. These
translated and culturally-adapted versions of validated
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instrument developers, when possible.
The final patient questionnaires began with stand-alone
questions concerning demographics. Generic HRQoL and
pain were assessed using validated PRO measures. Generic
HRQoL was assessed using the General Health-Related
Quality of Life EuroQoL(EQ)-5D-5L questionnaire [7].
This is a generic standardised measure of health status
developed by the EuroQoL group and applicable to a
wide range of health conditions and therapies. It com-
prises five dimensions (5D): Mobility, Self-care, Usual
activities, Pain/Discomfort and Anxiety/Depression.
EQ-5D health states can be converted into a single sum-
mary index value (utility) by applying a formula that essen-
tially attaches weights to each of the levels in each
dimension. This formula is based on the valuation of
EQ-5D health states from general population samples
[7]. A HRQoL utility value of “1” represents perfect
health; a value of “0” represents death. Subsequent nor-
malisation to a healthy population can provide negative
values indicating that the patient is feeling worse than
death. Pain and pain interference in daily life were
assessed using the Brief Pain Inventory Short Form
(BPI-SF) in adult patients [8] and the Adolescent
Pediatric Pain Tool (APPT) [9] in children. Fatigue was
assessed by questioning the patients on the number of
evenings in a week they were feeling extremely tired.
More detailed information regarding these validated
questionnaires is available as Additional file 1.
The caregiver questionnaire contained questions con-
cerning demographics, family relationships and social
characteristics, and self-reported time spent on caregi-
ving. The present paper will only shortly discuss results
regarding self-reported time spent on caregiving.
Statistical analysis
The present paper presents the outcomes of the demo-
graphic and clinical characteristics of the patients and
the outcomes of the validated PRO measures and care-
giver time.
Frequency distributions (number and percentage of pa-
tients in each category) were used for categorical variables
and descriptive statistics (mean, median, standard de-
viation/error [SD/SE], minimum and maximum scores)
for continuous and count variables. Responses to open-
ended questions were listed. For validated instruments,
scores were calculated according to the instrument’s scor-
ing guidelines. For more information, see Additional file 1.
Unpaired (type 3) t-tests were used to calculate P-
values for differences in outcomes between the follo-
wing mobility groups in adults and children: patients
never using a wheelchair vs. patients using a wheel-
chair only when needed vs. patients always using a
wheelchair.Results
Demographics and clinical characteristics
Completed questionnaires were received from 27 adults
and 36 children. The largest number of respondents (38%)
came from Germany (Additional file 2). Of the adult pa-
tients, about half (52%) were between ages 18 and 24 years.
The vast majority of adult patients (85%) lived with their
parents, while 7.4% lived alone. Practically all patients (92-
96%) showed short stature (Additional file 3) with a mean
height in adult patients of 115.1 cm (Additional file 2).
Bone deformity was present in approximately three in four
patients, while abnormal gait was more prevalent in adult
patients (96%) than in children (75%). Other common
clinical manifestations, occurring in ≥40% of adults or
children, were joint pain, difficulty in joint movement/
joint stiffness or joint laxity/hypermobility, eye problems,
fatigue/low stamina, difficulty breathing, cervical spine in-
stability, hearing loss and dental problems. In both adults
and children, joint laxity was most common at the wrists,
fingers, ankles, knees and elbows; joint stiffness was par-
ticularly common in adults, mostly in the shoulders and
back or cervical spine.
Additional file 2 gives information on the mobility of
the patients. Thirty % of adults and 25% of children used a
walking aid, most commonly crutches or a walker in
adults and a walker, braces, ankle foot orthoses or splints
in children. Wheelchair use increased with age, with most
adult patients (85%) using a wheelchair. In adults, 39% of
wheelchair users used their wheelchair always and 61%
used it only when needed; in children, 13% of wheelchair
users used it always and 88% used it only when needed.
HRQoL vs. mobility/wheelchair use and employment status
Analysis of the EQ-5D-5L questionnaire showed that in
both adult patients and children the HRQoL was most
negatively affected in the domains Mobility, Self-care and
Usual activities (Additional file 4). Adults who did not use a
wheelchair had a statistically significantly better HRQoL
than those who used a wheelchair only when needed, 0.846
vs. 0.582 (P = 0.0115; Figure 1a), respectively. This was not
observed in children (Figure 1b). Patients who always used
their wheelchair, both adults and children, reported statisti-
cally significantly lower HRQoL than those who use their
wheelchair only when needed (0.057 vs. 0.582 for adults
and-0.180 vs. 0.664 for children, both P = 0.0007; Figure 1),
respectively. The finding that Self-care is heavily affected in
adult patients using a wheelchair always was also confirmed
by caregivers, showing that average caregiving time for
these patients is much higher (13.8 hours during weekdays)
than for those not using a wheelchair (1.3 hours) or using a
wheelchair only when needed (3.9 hours; Additional file 5).
Of the 27 adult patients, 14 were unemployed and 12
were employed; employment status was missing for 1
patient. Unemployed adult patients had a statistically
a b
Figure 1 Health-related quality of life (HRQoL) measured using the EQ5D-5L questionnaire in adults (a) and children (b) with Morquio
A according to wheelchair use/mobility level. A score of 1 indicates “perfect health”, a score of 0 indicates “death”. Negative values indicate
“feeling worse than death”. Presented as mean value and standard error of the mean.
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(Figure 2). Employed patients were more likely to be ac-
tive and mobile; 67% of employed patients used a wheel-
chair vs. 100% of unemployed patients; 2 of the 9 patients
(22%) who always used a wheelchair were employed vs. 6
of the 13 patients (50%) using their wheelchair only when
needed.
Pain, pain interference and fatigue vs. mobility/
wheelchair use
Joint pain was experienced by 74% of adult patients and
64% of children (Additional file 3). This was related to
wheelchair use and intensity of wheelchair use, withFigure 2 Health-related quality of life (HRQoL) measured using the EQ
to employment status. A score of 1 indicates “perfect health”, a score of
Presented as mean value and standard error of the mean.slightly different results between adults and children. In
adults, non-wheelchair users had milder pain, took less
pain medication and/or had less body parts affected by
pain than patients who used a wheelchair (Figure 3a
and Additional file 6). Within the group of wheelchair
users, those who used their wheelchair always reported
pain less frequently, had milder pain and used less pain
medication than those who use their wheelchair only
when needed (Figure 3a and Additional file 6). More
mobile wheelchair users (using a wheelchair only when
needed) also reported more widespread pain (i.e. in
more body parts) than patients using their wheelchair
always (of whom most patients reported pain around5D-5L questionnaire in adult patients with Morquio A according
0 indicates “death”. Negative values indicate “feeling worse than death”.
a b
Figure 3 Pain severity (a) and pain interference with daily activities (b) in adults with Morquio A according to wheelchair use/mobility
level. Pain severity and pain interference were evaluated using the Brief Pain Inventory (BPI); 1 = no pain/no pain interference, 10 = worst pain
ever/complete pain interference. Pain interference scores were unavailable for 2 of the 4 patients in the “no wheelchair” and for 3 of the 9
patients in the “always wheelchair” groups. Presented as mean score and standard error of the mean.
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adult wheelchair users, pain interference scores reduced
with increased mobility, with patients always using a
wheelchair having the greatest pain interference with
daily activities (Figure 3b). In children, those who used
their wheelchair always had less severe pain (mean
APPT pain severity score of 1.00 ± SE 1.00) than those
who did not use a wheelchair (4.38 ± 0.72, P = 0.049)
or used their wheelchair only when needed (4.00 ± 0.75,
P = 0.054). The child non-wheelchair users did not only
have numerically the highest pain severity, but also
(slightly) more frequently reported pain across different
parts of the body than wheelchair users, including the
spinal area (63% vs. 57% of patients), lower extremities
(100% vs. 93% of patients), upper extremities (69% vs.
43% of patients) and head and neck area (56% vs. 43%
of patients).
Fatigue/low stamina was reported frequently by both
adults (63%) and children (69%; Additional file 3). The
impact of wheelchair use on fatigue and/or energy level
followed the same pattern as for pain: better mobility
was associated with more fatigue. Adults who always
used their wheelchair had higher energy levels (i.e. lower
proportion of patients feeling extremely tired on 1 or
more evenings per week) than those who used their
wheelchair only when needed (Additional file 7). The en-
ergy level in the adults that did not use a wheelchair was
in between that of those using a wheelchair always and
those using it only when needed. The results in children
were comparable. None of the children always using a
wheelchair felt extremely tired on 1or more evenings per
week as compared to the majority of children who were
more mobile (Additional file 7).Discussion
The clinical features reported in this international PRO
survey support the findings in natural history studies
that Morquio A is a progressive, multi-organ/systemic,
heterogeneous disease manifesting not only in the mus-
culoskeletal system (as bone and joint abnormalities) but
also affecting the eyes, ears, teeth and (cardio)respiratory
system [3,4]. The most frequently reported clinical ma-
nifestations, occurring in the majority of patients, were
short stature, bone deformity, joint abnormality (both la-
xity and stiffness), eye problems, cervical spine instability
and respiratory problems. The clinical characteristics of
the children included in the present survey are in line
(Additional file 8) with those from 2 large multi-national
natural history studies, i.e. the International Morquio A
Registry [3] and the MorCAP study [4]. The International
Morquio A Registry included 326 patients with a median
age of 11 years for males and 16 years for females [3]. The
MorCAP study included 325 patients with a median age
of 11.6 years [4]. The mean height of the children in this
survey was 109.9 cm (range 84 to 162.5 cm) compared to
104.2 cm (range 77.8 to 180.2 cm) in the MorCAP study
[4]. The mean height of the adults in this survey was
115.1 cm (± standard deviation [SD] of 25.8) compared to
122.5 (± SD 22.5) cm in men and 116.5 (± SD 20.5) cm in
women over 18 years old in the International Registry and
compared to 176.2 (± SD 6.1) cm and 163.1 (± SD 5.4) cm
in healthy controls at 18 years [3].
The survey confirmed that these multi-systemic clinical
manifestations generally lead to abnormal gait (in 75-96%
of patients) and increasing disability, with patients becom-
ing increasingly dependent on walking aids and, in par-
ticular, a wheelchair when they get older. Forty-four % of
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adults. In the natural history studies, respectively 31% [3]
and 45% [4] used a wheelchair. The increasing disability
and reliance on a wheelchair has a major impact on the
patients’ independence, illustrated by the fact that the vast
majority (85%) of the adult patients in this survey still
lived with their parents.
The multi-systemic clinical manifestations of the pa-
tients included in the survey were not only associated
with increasing disability and reduced mobility, they also
caused pain across a range of body parts and fatigue in
most patients.
Taking into account the debilitating nature of Morquio
A, it is not surprising that the patients included in the
survey had a reduced HRQoL as measured by the vali-
dated EQ-5D-5L questionnaire versus the general popu-
lation. HRQoL was affected considerably more in some
patients than in others, reflecting the variability in their
ability to remain independently mobile, i.e. to move
without using a wheelchair. Whereas the HRQoL utility
value in adult non-wheelchair users was still relatively
good (0.846), it was statistically significantly reduced if
patients had to use a wheelchair and approached a feel-
ing of death (0.057) when the wheelchair was used al-
ways. This negative impact of wheelchair use on HRQoL
was mostly driven by worse scores for the domains Mo-
bility, Self-care and Usual activities. The great impact of
wheelchair use on self-care was confirmed by the finding
that the dependence of patients on caregivers increased
with increasing wheelchair use. The average number of
caregiving hours for adult patients increased from
1.3 hours on a weekday in non-wheelchair users to
3.9 hours if the wheelchair was used only when needed
and up to 13.8 hours (practically all waking hours of the
day) when the wheelchair was used always. Another fac-
tor that may have influenced the very low HRQoL in the
patients who had to use their wheelchair always is em-
ployment status. The survey showed that adult patients
who had to use their wheelchair always had a very high
chance of being unemployed, which was associated with
a lower HRQoL than being employed. The impact of
wheelchair use on QoL was also shown in a study of 210
adults with Pompe disease which used the Short-Form
(SF) 36 to measure HRQoL [10]. In this study, wheel-
chair users had significantly lower physical and social
functioning scores than non-wheelchair users.
The validated EQ-5D-5L has been used in many other
(chronic) disease areas to evaluate HRQoL. The mean
HRQoL utility value of the adult patients in this survey
who used their wheelchair only when needed (0.582) was
worse than that reported for patients with chronic ischae-
mic heart disease (0.640) or non-insulin dependent dia-
betes mellitus (0.670) [11] and only slightly better than
that of patients with moderate to severe rheumatoidarthritis (RA; 0.489) [12] or with multiple sclerosis (MS)
requiring a walking aid (0.460) [13]. The HRQoL of the
adult Morquio A patients who always needed a wheelchair
in this survey (0.057) was only slightly better than that of
MS patients who are bed ridden or completely immobile
(-0.049) [13]. Arne et al. who evaluated HRQoL in patients
with chronic diseases such as chronic obstructive pulmo-
nary disease (COPD), RA and diabetes mellitus also con-
cluded that physical inactivity increases the burden of
disease [14].
The most mobile adult patients (i.e. the non-wheelchair
users) demonstrated better HRQoL versus patients who
used a wheelchair. This was accompanied by lower pain
severity scores on the BPI-SF. The adult patients using a
wheelchair only when needed had more severe and more
widespread pain than the patients always using a wheel-
chair but their pain interference score was lower. This
suggests that adult Morquio A patients try to tolerate pain
as long as independence (from their wheelchair and care-
givers) and mobility are retained. However, once pain af-
fects independence, there is a steep decrease in QoL. As
the pain interference analysis only included 2 adult pa-
tients not using a wheelchair, no conclusions can currently
be made regarding pain interference in this group. In the
adult patient group, the EQ-5D Pain/Discomfort domain
scores did not follow the pain severity scores obtained by
the BPI-SF for the different mobility categories. Most
likely, this is due to the fact that the Pain/Discomfort
score of the EQ-5D-5L is based on a single question
whereas the BPI-SF comprises different questions to assess
pain severity and will be able to capture more subtle dif-
ferences between patients.
The results for children using a wheelchair were in line
with those in adults using a wheelchair. Children who
used their wheelchair always experienced less severe and
less widespread pain and were less frequently feeling ex-
tremely tired at the end of the day than those who used
their wheelchair only when needed. However, unlike what
was seen in adults, HRQoL in children using a wheelchair
only when needed was better than in children not using a
wheelchair. This is probably due to the fact that children
not using a wheelchair had more severe pain (reflected in
both the APPT pain severity score and the EQ-5D-5L
Pain/Discomfort domain score) and pain across more
body parts than those using a wheelchair only when
needed. The fact that adults who always used a wheelchair
had more severe pain than children and were more often
feeling extremely tired at the end of the day may reflect
the progression of the disease over time/with age.
This PRO survey is the first study in patients with Mor-
quio A to show that although using a wheelchair all of the
time reduces pain severity and distribution and tiredness
at the end of the day due to limited functional activity, it
also considerably reduces HRQoL. Therefore, efforts
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to be independently mobile (e.g. by pain management and
appropriate use of walking aids) in these patients while
managing their energy level. Studies in patients with MS
showed that greater walking and mobility problems were
associated with higher unemployment rates, increased re-
quirement for caregiver support and higher healthcare re-
source utilisation and that interventions improving
mobility could have a significant impact on patients, care-
givers and society as a whole [15]. Findings from these
studies on MS are directly applicable to that of the Mor-
quio A patient population studied here. It should be noted
that recruiting through patients advocacy/support groups
and physicians may have resulted in recruitment bias in
the present study. Also, the results of the present survey
should be interpreted in light of the relatively low number
of patients included (even for this ultra-rare disease) and
the facts that for some assessments information was miss-
ing for some patients and the questionnaires were not vali-
dated specifically for Morquio A. Nevertheless, even with
this low patient number, the difference in QoL between pa-
tients with different levels of mobility was statistically sig-
nificant, suggesting a very strong association between
wheelchair use and QoL. The next critical evaluation will
be to try and equate this information with currently
used clinical trial outcome measures like the 6-minute
walk test/distance (6MWT/6MWD). This has been
done for Duchenne muscular dystrophy and has shown
that when looking at heterogeneous disorders the im-
provements in 6MWT will be very variable [16]. This
study concluded that “At lower levels of function,
smaller increases in 6MWD result in a meaningful
change in quality of life (QoL) instrument scores. At
higher levels of function, larger increases may be neces-
sary to achieve the same QoL change score”.
Conclusions
The HRQoL of Morquio A patients is mainly driven by the
ability to remain independently mobile without using a
wheelchair. QoL is dramatically reduced in patients who
use their wheelchair always. Even slightly better mobility
(i.e. using a wheelchair only when needed) improves QoL
dramatically. Although wheelchair use can considerably
reduce pain, clinicians should be aware of the detrimental
impact on the patient’s QoL and should not encourage pa-
tients to go down this route too readily. Maintenance of
functional capacity and mobility paired with better pain
management are likely to improve QoL.
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